Special Issue "Novel Melatonin Based Therapies"

A special issue of Diseases (ISSN 2079-9721).

Deadline for manuscript submissions: 31 August 2020.

Special Issue Editors

Prof. Dr. Alejandro Romero Martínez
E-Mail Website
Guest Editor
Sección Departamental de Farmacología y Toxicología, Facultad de Veterinaria, Universidad Complutense de Madrid, Avda. Puerta de Hierro s/n, 28040-Madrid, Spain
Interests: melatonin; stroke; neurodegenerative diseases; neurotoxicity mechanisms; oxidative stress; neuroinflammation; metals; neuroblastoma; chemical warfare agents
Prof. Dr. Russel J. Reiter
E-Mail Website
Guest Editor
Department of Cellular & Structural Biology, The UT Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
Interests: melatonin; free radicals of disease processes and aging; oxygen derivatives
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Melatonin has emerged in the last decade as a promising agent to counteract most of the physiopathological events that trigger several disorders. Most of the beneficial molecular functions exerted by melatonin are due to the following: Its small size and amphiphilic nature allow the molecule to easily diffuse through any membrane, reaching cytosolic, mitochondrial and nuclear compartments. It is a potent scavenger of free radicals, both directly and indirectly, inhibiting the activity of prooxidative enzymes and stimulating antioxidant enzymes through interactions with two high-affinity G protein-coupled receptors. It can activate or inhibit crucial signaling cascades involved in cell protection and survival. It plays a dominant role as a circadian neuroendocrine transducer, immune system stimulator, and effective anti-inflammatory agent. It displays multiple direct epigenetic actions. Its efficacy is strengthened by its very low toxic hazard; even at high doses, serious adverse side effects have not been reported. In this Special Issue, we will focus on the use of melatonin as an adjuvant treatment in a wide variety of diseases, which could be of critical importance for the development of novel therapeutic strategies.

This Special Issue will serve as a forum to bring together researchers of different fields to share advances in the knowledge of the therapeutic uses of melatonin.

Prof. Dr. Alejandro Romero Martínez
Prof. Dr. Russel J. Reiter
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • melatonin
  • adjuvant therapy
  • cancer
  • neurodegenerative diseases
  • gastrointestinal diseases
  • sleep disorders
  • cardiovascular and blood diseases
  • diabetes
  • immune system-related diseases
  • infectious diseases
  • mitochondrial diseases
  • clinical trials

Published Papers

This special issue is now open for submission.
Back to TopTop